Zhejiang Teruisi Pharmaceutical Inc.
6 clinical trials · Sponsor
◉ Watch Zhejiang Teruisi Pharmaceutical Inc.
| Record | Firm | Date |
|---|---|---|
| A Phase 2 Study of TRS005 in Patients With CD20-positive R/R DLBCL. (NCT06886139) | Zhejiang Teruisi Pharmaceutical Inc. | 2025-09-01 |
| A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL (NCT07035379) | Zhejiang Teruisi Pharmaceutical Inc. | 2025-09-01 |
| A Study Assessing the Interchangeability Between TRS003 and Bevacizumab® For CRC (NCT05378867) | Zhejiang Teruisi Pharmaceutical Inc. | 2022-08-01 |
| A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL. (NCT05395533) | Zhejiang Teruisi Pharmaceutical Inc. | 2020-09-08 |
| A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLC (NCT04416035) | Zhejiang Teruisi Pharmaceutical Inc. | 2020-08-17 |
| A Study to Compare Pharmacokinetic and Safety of TRS003 to China-approved Bevacizumab and US-licensed Avastin® (NCT03882424) | Zhejiang Teruisi Pharmaceutical Inc. | 2018-06-12 |
Track Zhejiang Teruisi Pharmaceutical Inc. automatically
Every clearance here is in the API, with alerts when new ones post.